OPTN/SRTR 2019 Annual Data Report: Heart
Abstract
The new adult heart allocation policy was approved in 2016 and implemented in October 2018. This year’s Annual Data Report provides early insight into the effects of this policy. In 2019, new listings continued to increase, with 4086 new candidates. Also in 2019, 3597 heart transplants were performed, an increase of 157 (4.6%) from 2018; 509 transplants occurred in children and 3088 in adults. Short- and long-term posttransplant mortality rates improved. Overall, Mortality rates for adult recipients were 6.4% at 6 months and 7.9% at 1 year for transplants in 2018, 14.4% at 3 years for transplants in 2016, and 20.1% at 5 years for transplants in 2014. Mortality rates for pediatric recipients were 6.3% at 6 months and 8.2% at 1 year for transplants in 2018, 10.3% at 3 years for transplants in 2016, and 17.8% at 5 years for transplants in 2014.
Introduction
The new adult heart allocation policy was approved in 2016 and implemented in October 2018 to better stratify heart transplant candidates and broaden sharing for higher-urgency statuses to reduce waiting list mortality. While it is too early to discern the impact of the new policy, the more granular data being collected as part of the new system are anticipated to allow improved analyses of outcomes and risk factors, which will contribute to a more dynamic policy. The current Annual Data Report provides an early glimpse into the trends of heart transplant candidates and recipients under the new allocation system.
Adult Heart Transplant
Waiting List Trends
From 2008 to 2019, the number of new listings for heart transplant increased by 42.5%, from 2867 to 4086 (Figure HR 1). The number of candidates awaiting heart transplant increased by 42.6% over 2008 to 2019, from 5304 to 7562 (Figure HR 2). Some notable demographic trends in heart transplant since 2008 include stable proportions of women and men (Figure HR 4), lower proportions of whites (70.4% in 2008 to 60.4% in 2019), higher proportions of blacks, (19.1% to 26.0%) and Hispanics (7.4% to 9.7%) (Figure HR 5), a slight increase in patients with congenital heart disease, and a substantial decrease in patients with coronary artery disease (Figure HR 6). The proportion of candidates diagnosed as having cardiomyopathy continued to increase. Cardiomyopathy is the most common diagnosis among candidates, comprising 59.7% in 2019.
In 2019, 78.4% of candidates had been on the waiting list for less than 1 year, similar to 2009. In 2009, 14.6% of candidates had been on the waiting list for 2 years or longer; this proportion gradually declined to 12.0% in 2019, the lowest in the past decade (Figure HR 7). The proportion of status 1A candidates awaiting transplant continued to increase, while the proportion of status 1B candidates gradually increased, then declined slightly in 2018 (Figure HR 8). Note that new status groups in use as of October 2018 were converted to former status 1A, 1B, and two equivalents for the 2018 data point. New status groups 1-3 were converted to old status 1A, new status 4 to old status 1B, and new status 5 and 6 to old status 2. The proportion of candidates with ventricular assist devices (VADs) at listing increased from 13.5% in 2009 to 37.1% in 2019 (Table HR 2). Sex distribution did not change appreciably: in 2019, women comprised 26.1% of heart transplant candidates (Figure HR 4). As of December 31, 2019, 85.1% of candidates resided in a metropolitan area; 61.5% lived within 50 miles of the transplant center, compared with 57.2% in 2009 (Table HR 1). Numbers of candidates with a previous heart transplant declined from 4.1% in 2009 to 2.8% in 2019 (Table HR 3). At year-end 2019, 253 candidates were listed for heart-kidney transplant, a substantial increase since 2009. The number of heart-lung candidates remained stable over this period, with 74 candidates waiting in 2019 (Table HR 3).
From 2017 to 2019, the number of patients removed from the transplant list increased, but fewer were removed due to improvement or being too ill for transplant (Table HR 5). Compared with 2017, 103 fewer patients died on the waiting list in 2019.
The distribution of candidates by status on December 31, 2019, is shown in Table HR 2. At the end of 2019, 4 patients (0.1%) were listed as status 1, and 48 (1.4%) were status 2. Fewer patients were listed in the highest-urgency categories under the new allocation system, with 50.5% listed as status 4. The number of patients receiving any life support before transplant increased slightly, from 2431 in 2017 to 2519 in 2019, although they represented a smaller proportion of candidates in 2019 than in 2017 (Table HR 7). Of these, 1034 (33.5%) had left-VADs (LVADs), a decrease of 324 over the 2-year period. There was a shift toward intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO), and there was a substantial increase in ventilator support before transplant between 2017 and 2019. In 2019, candidates on IABP comprised nearly one-third of all candidates on life support (Table HR 7).
Since 2015, overall deceased-donor heart transplant rates have increased, to a decade high of 89.5 per 100 waitlist years in 2019 (Figure HR 12). This trend was similar for all age-groups; however, the increase was greatest in candidates 65 and older, with 74.3 per 100 waitlist years in 2015 to 132.2 in 2019 (Figure HR 13). For most groups, transplant rates since 2008 reached a nadir in 2014 and 2015 and have increased since. Transplant rates for Asians exceed that for other ethnic groups (Figure HR 14).
Transplant rates have consistently been highest for candidates with blood type AB (276.6 per 100 waitlist years in 2019), those listed as status 1A under the previous allocation system in 2018 (302.2 per 100), and those now listed as status 1 (1649.0 per 100) (Figure HR 16, Figure HR 18, Figure HR 19). In 2019, blood type O candidates underwent transplant at a rate of 59.7 per 100 waitlist years, less than half the rate of blood type A and B candidates. Despite these differences, transplant rates for all blood types have increased since 2015 (Figure HR 16). From 2008 to 2012, candidates residing in metropolitan areas had higher transplant rates than those in non-metropolitan areas; however, since then, the rates have been more closely aligned. In 2019, the transplant rate was 89.6 per 100 waitlist years for those residing in metropolitan areas and 86.6 per 100 in non-metropolitan areas (Figure HR 21).
The median wait time in 2018-2019 was 5.1 months, the lowest in the past decade. Women typically had a shorter median wait than men and in 2018-2019 underwent transplant at a median of 3.5 months, compared with men (5.9 months) (Figure HR 23). The median wait for candidates with blood type O declined substantially over the past 5 years, from 21.6 months in 2014-2015 to 11.7 months in 2018-2019; however, the median wait for blood type O still far exceeded that of all other blood types (Figure HR 24). Candidates with a body mass index (BMI) of 35 kg/m2 or greater also had longer median waits than other candidates. In 2008-2009, the median wait for candidates with BMI ≥35 kg/m2 was 32.7 months, which declined to 9.7 months in 2018-2019. Candidates with BMI <18.5 kg/m2 had the shortest median wait (1.8 months) (Figure HR 26). The proportion of candidates who underwent transplant within 1 year of listing has varied but has increased since 2014. In 2018, 56.8% of candidates underwent transplant within 1 year of listing (Figure HR 27). When stratified by donation service area (DSA), the proportion of candidates undergoing transplant within 1 year of listing in 2018 was 23.1% to 85.5% (Figure HR 28). Similar variability occurred by state (22.2% to 100%) (Figure HR 29).
Pretransplant mortality declined from 17.4 deaths per 100 waitlist years in 2008 to 8.3 per 100 in 2019 (Figure HR 30). Pretransplant mortality declined for all groups starting in 2009. It was lowest for candidates aged 18-34 years (6.7 per 100 waitlist years) and 35-49 (6.8 per 100) and those listed as status 4 (6.1 per 100) or 6 (6.1 per 100) (Figure HR 31, Figure HR 36). Deaths before transplant declined by more than 50% for all age-groups from 2008 to 2019 (Figure HR 31) and declined substantially over the past decade for black, Hispanic, and Asian candidates. Asians had the largest decline in pretransplant mortality rate, from 28.7 deaths per 100 waitlist years in 2008 to 10.4 deaths per 100 in 2019. Pretransplant mortality was lowest for Hispanics (6.5 deaths per 100) in 2019 (Figure HR 32). Aside from occasional fluctuations, pretransplant mortality rates have been similar between men and women, at 8.15 deaths per 100 waitlist years and 8.36 per 100 in 2019, respectively (Figure HR 33).
Despite a large decline in pretransplant mortality among all statuses under the previous system, patients in the highest-urgency categories still die far more often than those with other statuses. In 2017-2018, candidates listed as status 1A had a pretransplant mortality rate of 29.3 deaths per 100 waitlist years, while status 1B and 2 candidates were similar, at 8.3 deaths per 100 and 7.1 per 100, respectively (Figure HR 35). In 2019, status 1 candidates under the new system had a pretransplant mortality rate of 113.5 deaths per waitlist years, followed by status 2 (42.4 per 100), 5 (33.9 per 100), and 3 (17.2 per 100), respectively (Figure HR 36). It is not possible to compare the pretransplant mortality rates between the new and old systems because of the change in both criteria and practice. From 2006 to 2008, policy changes regarding broader sharing and US Food and Drug Administration approval of LVADs resulted in a change in practice. The large decline in pretransplant mortality likely reflects the combined effect of those changes.
In 2019, 20.6% of candidates died within 6 months of removal from the waiting list (whose removal reasons were any reasons other than transplant or death), more than in the previous 2 years (Figure HR 40). After a peak in 2013, deaths after removal from the list declined despite the increase in 2019.
Donor Trends
The number of deceased-donor hearts continued to increase, with 3635 in 2019, the highest number to date and an increase of 63.6% since 2008 (Figure HR 43). While the number of donors increased in all age-groups since 2008, the greatest increase remained in donors 30-39 years, from 381 in 2008 to 966 in 2019 (Figure HR 44); the highest proportion of donors, 34.8%, was in donors 18-29 years (Figure HR 45). About 70% of donors are men (Figure HR 46). There is little variation by race; most donors are white, which reflects population demographics (Figure HR 47). The proportion of pediatric hearts allocated to adults varied by DSA and in 2015-2019 was 0 to 71.4 (Figure HR 48).
The discard rate (ie, proportion of recovered hearts not transplanted) has fluctuated over the past decade and in 2019 was 0.85% (Figure HR 49). The discard rate for donors aged 55 and older has declined and in 2019 was 2.06, compared with 1.24 in those 40-54 years. Hearts from donors <18 years were least likely to be discarded, at a rate of 0.35 (Figure HR 50). Women’s hearts tended to be discarded more often than men’s, although this has varied (Figure HR 51). Discard rates for Asian donor hearts have fluctuated, but there has been no noticeable race-based trend (Figure HR 52).
In 2019, anoxia slightly exceeded head trauma as the most common cause of death among heart donors (42.8% vs 41.1%) (Figure HR 57).
Trends in Adult Heart Transplant
The number of heart transplants performed in the United States has steadily risen, and in 2019 was 3597 (Figure HR 58). There has been an increase in all age groups; however, recipients 65 and older had the greatest relative increase over the past decade, with 596 transplants in 2019, and 85.1% increase since 2010 (Figure HR 59). The median per-center transplant volume has increased since 2014, from 14 to 23 in 2019 (Figure HR 67). As median volumes increase, the proportion of transplants performed at low-volume centers has declined and the proportion performed at median to high volume centers has increased. In 2019, centers with volumes of 1-9 transplants performed only 2.8% of all procedures, while centers performing 30 or more transplants per year accounted for 63.0% of all heart transplants (Figure HR 68).
The proportion of patients on any type of life support, including inotropic support, declined from 85.6% in 2017 to 81.6% in 2019, although the absolute number increased. There is a growing shift in the use of temporary circulatory support compared with previous years. Notably, LVAD at transplant has declined from 47.8% to 33.5%, while IABP use increased from 8.3% to 29.7%, and ECMO increased from 1.2% to 6.0%. Ventilator use has also increased, from 0.8% to 2.5% (Table HR 7). The typical heart transplant recipient in 2019 was a man (71.6%), white (62.3%), 50-64 years old (47.3%), had private insurance (48.6%), resided in a metropolitan area (85.3%), had cardiomyopathy (62.5%) and blood type A (40.4%), and was status 2 at transplant (47.2%) (Table HR 8, Table HR 9). Between 2009 and 2019, proportions of women and blacks have increased from 24.4% to 28.4% and from 19.3 to 23.1%, respectively (Table HR 8).
Adult Post-transplant Survival and Morbidity
Adult death rates after heart transplant continued to decline; of those who underwent transplant in 2018, 6.4% died by 6 months, and 7.9% died by 1 year. Death rates at all time points have improved over the past decade (Figure HR 69). In patients who underwent transplant from 2012 to 2014, early survival was similar among all age-groups; however, in recipients 65 and older, 1-year survival rates declined compared with younger age groups. The one-year survival rate in recipients aged 35-49 was 90.4%. One-year survival was greatest in recipients aged 18-34, at 90.9%. At 2 years, survival was highest in recipients aged 50-64 (87.6%) and remained so up to year 5, at 80.2%. Recipients aged 18-35 had the lowest 5-year survival rate, at 77.3% (Figure HR 70). Recipients categorized as “other” race had the best 1-year survival rate (93.9%), followed by Asians (92.7%) (Figure HR 71). By year 5, blacks fared substantially worse (75.9%), followed by whites (80.0%). Recipients with congenital heart disease had the lowest 1- and 5-year survival rate (82.2% and 74.2%), while those with valvular heart diseases fared best (84.5%) at 5 years (Figure HR 72). Men and women had comparable survival at all time points (Figure HR 73). Survival in recipients with VADs was 88.4% at 1 year, compared with 90.9% in those without VADs, a trend that appeared within 30 days and continued through 5 years (Figure HR 74). Status 1B recipients fared better than those of other statuses (previous system) (Figure HR 75). The number of survivors after heart transplant continues to increase. On June 30, 2019, 35,713 recipients were alive with a functioning graft, versus 23,315 in 2008 (Figure HR 77). Acute rejection occurred in 25.1% of recipients by 1 year and was most common in adults aged 18-49 (Figure HR 78). Of adult recipients undergoing transplant from 2013 to 2017, PTLD occurred in 0.87% by year 5 and was most common (3.0%) in EBV-negative recipients (Figure HR 80).
Pediatric Heart Transplant
Pediatric Waitlist Trends
In 2019, 694 new pediatric candidates were added to the heart transplant waiting list (Figure HR 81). In 2019, a total of 1087 candidates aged 17 years or younger were awaiting heart transplant (Figure HR 82). The largest pediatric age groups on the waiting list in 2019 were 12-17 years (30.1%) and younger than 1 year (30.0%), followed by 1-5 years (23.3%), and 6-11 years (16.7%) (Figure HR 83). Just over half of pediatric heart transplant candidates were white, 19.6% were black, 19.3% were Hispanic, and 3.3% were Asian (Figure HR 84). The proportion of pediatric heart transplant candidates with congenital defects increased from 46.4% in 2008 to 55.7% in 2019 (Figure HR 85). Considering trends over time, ages and races of waitlisted candidates remained relatively unchanged (Table HR 11). For candidates waiting on December 31, 2019, congenital defect was the leading cause of heart disease at 62.4%, increased from 49.2% in 2009 (Table HR 12). Regarding medical urgency, almost half (46.6%) of pediatric heart transplant candidates were listed as status 1A (Figure HR 88). The proportions listed as status 1B and status 2 increased in 2016 and later, likely reflecting changes to pediatric heart allocation policy implemented in 2016. A smaller proportion of candidates were listed for heart-lung transplant in 2019, 1.6% compared with 4.1 % in 2009 (Table HR 13). Among the 672 candidates removed from the waiting list in 2019, 519 (77.2%) were removed due to undergoing transplant, 55 (8.2%) died, 43 (6.4%) were removed due to improved condition, and 28 (4.2%) were considered too sick to undergo transplant (Table HR 14, Table HR 15).
In 2019, the majority (74.0%) of pediatric heart transplant candidates on the waiting list had been waiting for less than 90 days (Figure HR 87). Just over 70% of pediatric candidates newly listed in 2016 underwent transplant within 3 years, 11.4% died, 14.3% were removed from the list, and 3.8% were still waiting (Figure HR 89). The rate of heart transplant among pediatric waitlist candidates remained relatively stable over the past decade and was 128.5 per 100 waitlist years in 2019 (Figure HR 90). Transplant rates varied by age; 2019 rates were highest for candidates aged 12-17 years at 153.1 transplants per 100 waitlist year, and followed by those aged younger than 1 year at 151.5 transplants per 100 waitlist years. The next are by those aged 6-11 years at 111.2 transplants per 100 waitlist years, and those aged 1-5 years at 94.6 transplants per 100 waitlist years (Figure HR 91). Pretransplant mortality decreased from 33.4 deaths per 100 waitlist years in 2008 to 13.9 in 2019 (Figure HR 94), with notable decreases for candidates aged younger than 1 year (Figure HR 95). Pretransplant mortality rates in 2019 varied by age, and were highest for candidates aged younger than 1 year at 21.0 deaths per 100 waitlist years, followed by 18.9 for ages 1-5 years, 8.4 for ages 12-17 years, and 5.9 for ages 6-11 years (Figure HR 95). By medical urgency status, pretransplant mortality was highest for status 1A (34.4 deaths per 100 waitlist years) and 1B (13.1) candidates, compared with 2.1 for status 2 candidates (Figure HR 98).
Pediatric Trends in Heart Transplant
Pediatric transplant recipients are defined as those aged less than 18 years at the time of transplant. The number of pediatric heart transplants performed each year continued to increase, to 509 in 2019 (Figure HR 100): 181 (35.6%) in recipients aged 11-17 years, 133 (26.1%) in recipients aged < 1 year, 115 (22.6%) in recipients aged 1-5 years, and 80 (15.7%) in recipients aged 6-10 years (Figure HR 101). In 2019, 25 of 137 total heart transplant programs performed pediatric heart transplants exclusively, 77 performed adult heart transplants exclusively, and 35 performed both adult and pediatric heart transplants (Figure HR 102). In 2019, 7.5% of transplants in recipients aged younger than 10 years, 12.0% in recipients aged younger than 15 years, and 15.9% in recipients aged younger than 18 years were performed at programs with volume of five or fewer pediatric transplants in that year (Figure HR 103). Over the past decade, the age, sex, and race/ethnicity of pediatric heart transplant recipients changed little (Table HR 16). Congenital defects remained the most common primary cause of disease, affecting 51.3% of recipients who underwent transplant in 2017-2019 (Table HR 17). The proportion who underwent transplant at status 1A declined slightly, from 82.2% in 2007-2009 to 80.3% in 2017-2019, while the proportion at status 1B increased from 10.5% to 16.2%, and the proportion at status 2 declined from 7.2% to 3.5%. VAD use at the time of transplant increased from 15.7% of transplant recipients in 2007-2009 to 32.4% in 2017-2019 (Table HR 17). The proportion of ABO-incompatible transplants in 2017-2019 increased to 10.5% from 4.0% a decade earlier (Table HR 18).
Over the past decade, induction therapy use increased to 83.7% of pediatric heart transplant recipients in 2019 (Figure HR 104). The initial immunosuppression regimens used most commonly in 2019 were tacrolimus, MMF, and steroids (53.2%), and tacrolimus and MMF (40.1%) (Figure HR 105).
Pediatric Posttransplant Survival and Morbidity
Among 2017-2018 pediatric heart transplant recipients, the rate of acute rejection in the first year was 21.2% overall; the highest rates were 23.7% in recipients aged 11-17 years, and 20.0% in recipients aged 6-10 years and younger than 6 years (Figure HR 107).
Recipient death occurred in 6.3% of patients at 6 months posttransplant and in 8.2% at 1 year among pediatric heart transplants performed in 2018, in 10.3% of patients at 3 years for transplants performed in 2016, in 17.8% of patients at 5 years for transplants performed in 2014, and in 28.7% of patients at 10 years for transplants performed in 2009 (Figure HR 109). Overall, 1-year and 5-year patient survival were 92.0% and 84.1%, respectively, among recipients who underwent transplant in 2012-2014 (Figure HR 110). By age, 5-year patient survival was 81.3% for recipients aged younger than 1 year, 85.1% for ages 1-5 years, 84.8% for ages 6-10 years, and 85.4% for ages 11-17 years (Figure HR 111).
Among pediatric heart transplant recipients 2017-2019, the combination of a CMV-positive donor and CMV-negative recipient occurred in 28.3% of transplants; for EBV, this combination occurred in 28.6% of transplants (Table HR 20). The overall incidence of PTLD was 4.5% at 5 years posttransplant; incidence was 5.7% among EBV-negative recipients and 3.5% among EBV-positive recipients (Figure HR 108).
Figure List
Waiting list
Figure HR 1. New candidates added to the heart transplant waiting listFigure HR 2. All adult candidates on the heart transplant waiting list
Figure HR 3. Distribution of adults waiting for heart transplant by age
Figure HR 4. Distribution of adults waiting for heart transplant by sex
Figure HR 5. Distribution of adults waiting for heart transplant by race
Figure HR 6. Distribution of adults waiting for heart transplant by diagnosis
Figure HR 7. Distribution of adults waiting for heart transplant by waiting time
Figure HR 8. Distribution of adults waiting for heart transplant by old medical urgency, 2008-2018
Figure HR 9. Distribution of adults waiting for heart transplant by BMI
Figure HR 10. Distribution of adults waiting for heart transplant by blood type
Figure HR 11. Distribution of adults waiting for heart transplant by prior transplant status
Figure HR 12. Overall deceased donor heart transplant rates among adult waitlist candidates
Figure HR 13. Deceased donor heart transplant rates among adult waitlist candidates by age
Figure HR 14. Deceased donor heart transplant rates among adult waitlist candidates by race
Figure HR 15. Deceased donor heart transplant rates among adult waitlist candidates by diagnosis
Figure HR 16. Deceased donor heart transplant rates among adult waitlist candidates by blood type
Figure HR 17. Deceased donor heart transplant rates among adult waitlist candidates by sex
Figure HR 18. Deceased donor heart transplant rates among adult waitlist candidates by former medical urgency groups (Status 1A, 1B, 2), through 2018
Figure HR 19. Deceased donor heart transplant rates among adult waitlist candidates by new medical urgency groups, 2019
Figure HR 20. Deceased donor heart transplant rates among adult waitlist candidates by height
Figure HR 21. Deceased donor heart transplant rates among adult waitlist candidates by metropolitan vs. non-metropolitan residence
Figure HR 22. Three-year outcomes for adults waiting for heart transplant, new listings in 2016
Figure HR 23. Median months to heart transplant for waitlisted adults by sex
Figure HR 24. Median months to heart transplant for waitlisted adults by blood type
Figure HR 25. Median months to heart transplant for waitlisted adults by old medical urgency at listing
Figure HR 26. Median months to heart transplant for waitlisted adults by BMI at listing
Figure HR 27. Percentage of adults who underwent deceased donor heart transplant within a given time period of listing
Figure HR 28. Percentage of adults who underwent deceased donor heart transplant within 1 year of listing, 2018, by DSA
Figure HR 29. Percentage of adults who underwent deceased donor heart transplant within 1 year of listing, 2018, by state
Figure HR 30. Overall pretransplant mortality rates among adults waitlisted for heart transplant
Figure HR 31. Pretransplant mortality rates among adults waitlisted for heart transplant by age
Figure HR 32. Pretransplant mortality rates among adults waitlisted for heart transplant by race
Figure HR 33. Pretransplant mortality rates among adults waitlisted for heart transplant by sex
Figure HR 34. Pretransplant mortality rates among adults waitlisted for heart transplant by diagnosis
Figure HR 35. Pretransplant mortality rates among adults waitlisted for heart transplant by former medical urgency groups (Status 1A, 1B, 2), through 2018
Figure HR 36. Pretransplant mortality rates among adults waitlisted for heart transplant by new medical urgency groups, 2019
Figure HR 37. Pretransplant mortality rates among adults waitlisted for heart transplant by metropolitan vs. non-metropolitan residence
Figure HR 38. Pretransplant mortality rates among adults waitlisted for heart transplant, by active/inactive status
Figure HR 39. Pretransplant mortality rates among adults waitlisted for heart transplant in 2019 by DSA
Figure HR 40. Deaths within six months after removal among adult heart waitlist candidates, overall
Figure HR 41. Deaths within six months after removal among adult heart waitlist candidates, by status at removal
Figure HR 42. Deaths within six months after removal among adult heart waitlist candidates, by age
Deceased donation
Figure HR 43. Overall deceased heart donor countFigure HR 44. Deceased heart donor count by age
Figure HR 45. Distribution of deceased heart donors by age
Figure HR 46. Distribution of deceased heart donors by sex
Figure HR 47. Distribution of deceased heart donors by race
Figure HR 48. Percent of pediatric donor hearts allocated to adult recipients, by DSA of donor hospital, 2015-2019
Figure HR 49. Overall rates of hearts recovered for transplant and not transplanted
Figure HR 50. Rates of hearts recovered for transplant and not transplanted by donor age
Figure HR 51. Rates of hearts recovered for transplant and not transplanted by donor sex
Figure HR 52. Rates of hearts recovered for transplant and not transplanted by donor race
Figure HR 53. Rates of hearts recovered for transplant and not transplanted by donor hypertension status
Figure HR 54. Rates of hearts recovered for transplant and not transplanted by donor BMI
Figure HR 55. Rates of hearts recovered for transplant and not transplanted by donor cause of death
Figure HR 56. Rates of hearts recovered for transplant and not transplanted, by donor risk of disease transmission
Figure HR 57. Cause of death among deceased heart donors
Transplant
Figure HR 58. Overall heart transplantsFigure HR 59. Total heart transplants by age
Figure HR 60. Total heart transplants by sex
Figure HR 61. Total heart transplants by race
Figure HR 62. Total heart transplants by diagnosis
Figure HR 63. Total heart transplants by former medical urgency groups, 2008-2018
Figure HR 64. Induction agent use in adult heart transplant recipients
Figure HR 65. Immunosuppression regimen use in adult heart transplant recipients
Figure HR 66. Total HLA A, B, and DR mismatches among adult deceased heart transplant recipients, 2015-2019
Figure HR 67. Annual adult heart transplant center volumes by percentile
Figure HR 68. Distribution of adult heart transplants by annual center volume
Outcomes
Figure HR 69. Patient death among adult heart transplant recipientsFigure HR 70. Patient survival among adult heart transplant recipients, 2012-2014, by age
Figure HR 71. Patient survival among adult heart transplant recipients, 2012-2014, by race
Figure HR 72. Patient survival among adult heart transplant recipients, 2012-2014, by diagnosis group
Figure HR 73. Patient survival among adult heart transplant recipients, 2012-2014, by sex
Figure HR 74. Patient survival among adult heart transplant recipients, 2012-2014, by VAD status
Figure HR 75. Patient survival among adult heart transplant recipients, 2012-2014, by medical urgency
Figure HR 76. Patient survival among adult heart transplant recipients, 2012-2014, by metropolitan vs. non-metropolitan recipient residence
Figure HR 77. Recipients alive with a functioning heart graft on June 30 of the year, by age at transplant
Figure HR 78. Incidence of acute rejection by 1 year posttransplant among adult heart transplant recipients by age, 2017-2018
Figure HR 79. Incidence of acute rejection by 1 year posttransplant among adult heart transplant recipients by induction agent, 2017-2018
Figure HR 80. Incidence of PTLD among adult heart transplant recipients by recipient EBV status at transplant, 2013-2017
Pediatric transplant
Figure HR 81. New pediatric candidates added to the heart transplant waiting listFigure HR 82. All pediatric candidates on the heart transplant waiting list
Figure HR 83. Distribution of pediatric candidates waiting for heart transplant by age
Figure HR 84. Distribution of pediatric candidates waiting for heart transplant by race
Figure HR 85. Distribution of pediatric candidates waiting for heart transplant by diagnosis
Figure HR 86. Distribution of pediatric candidates waiting for heart transplant by sex
Figure HR 87. Distribution of pediatric candidates waiting for heart transplant by waiting time
Figure HR 88. Distribution of pediatric candidates waiting for heart transplant by medical urgency
Figure HR 89. Three-year outcomes for newly listed pediatric candidates waiting for heart transplant, 2016
Figure HR 90. Overall deceased donor heart transplant rates among pediatric waitlist candidates
Figure HR 91. Deceased donor heart transplant rates among pediatric waitlist candidates by age
Figure HR 92. Deceased donor heart transplant rates among pediatric waitlist candidates by race
Figure HR 93. Deceased donor heart transplant rates among pediatric waitlist candidates by metropolitan vs. non-metropolitan residence
Figure HR 94. Overall pretransplant mortality rates among pediatric candidates waitlisted for heart
Figure HR 95. Pretransplant mortality rates among pediatric candidates waitlisted for heart transplant by age
Figure HR 96. Pretransplant mortality rates among pediatric candidates waitlisted for heart transplant by race
Figure HR 97. Pretransplant mortality rates among pediatrics waitlisted for heart transplant by diagnosis
Figure HR 98. Pretransplant mortality rates among pediatrics waitlisted for heart transplant by medical urgency
Figure HR 99. Pretransplant mortality rates among pediatric candidates waitlisted for heart transplant by metropolitan vs. non-metropolitan residence
Figure HR 100. Overall pediatric heart transplants
Figure HR 101. Pediatric heart transplants by recipient age
Figure HR 102. Number of centers performing pediatric and adult heart transplants by center's age mix
Figure HR 103. Pediatric heart recipients at programs that perform 5 or fewer pediatric transplants annually
Figure HR 104. Induction agent use in pediatric heart transplant recipients
Figure HR 105. Immunosuppression regimen use in pediatric heart transplant recipients
Figure HR 106. Total HLA A, B, and DR mismatches among pediatric deceased donor heart transplant recipients, 2015-2019
Figure HR 107. Incidence of acute rejection by 1 year posttransplant among pediatric heart transplant recipients by age, 2017-2018
Figure HR 108. Incidence of PTLD among pediatric heart transplant recipients by recipient EBV status at transplant, 2007-2017
Figure HR 109. Patient death among pediatric heart transplant recipients
Figure HR 110. Overall patient survival among pediatric deceased donor heart transplant recipients, 2012-2014
Figure HR 111. Patient survival among pediatric deceased donor heart transplant recipients, 2012-2014, by recipient age
Table List
Waiting list
Table HR 1. Demographic characteristics of adults on the heart transplant waiting list on December 31, 2009 and December 31, 2019Table HR 2. Clinical characteristics of adults on the heart transplant waiting list on December 31, 2009 and December 31, 2019
Table HR 3. Listing characteristics of adults on the heart transplant waiting list on December 31, 2009 and December 31, 2019
Table HR 4. Heart transplant waitlist activity among adults
Table HR 5. Removal reason among adult heart transplant candidates
Table HR 6. Percentage of adults who received transplant within 6 months from listing between January 1 and June 30 in 2019
Transplant
Table HR 7. Adult heart recipients on circulatory support before transplantTable HR 8. Demographic characteristics of adult heart transplant recipients, 2009 and 2019
Table HR 9. Clinical characteristics of adult heart transplant recipients, 2009 and 2019
Table HR 10. Transplant characteristics of adult heart transplant recipients, 2009 and 2019
Pediatric transplant
Table HR 11. Demographic characteristics of pediatric candidates on the heart transplant waiting list on December 31, 2009 and December 31, 2019Table HR 12. Clinical characteristics of pediatric candidates on the heart transplant waiting list on December 31, 2009 and December 31, 2019
Table HR 13. Listing characteristics of pediatric candidates on the heart transplant waiting list on December 31, 2009 and December 31, 2019
Table HR 14. Heart transplant waitlist activity among pediatric candidates
Table HR 15. Removal reason among pediatric heart transplant candidates
Table HR 16. Demographic characteristics of pediatric heart transplant recipients, 2007-2009 and 2017-2019
Table HR 17. Clinical characteristics of pediatric heart transplant recipients, 2007-2009 and 2017-2019
Table HR 18. Transplant characteristics of pediatric heart transplant recipients, 2007-2009 and 2017-2019
Table HR 19. Pediatric heart recipients on circulatory support before transplant
Table HR 20. Pediatric heart donor-recipient serology matching, 2017-2019
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Age: 18-34 years | 299 | 11.0% | 374 | 11.0% |
Age: 35-49 years | 610 | 22.4% | 815 | 24.1% |
Age: 50-64 years | 1393 | 51.0% | 1642 | 48.5% |
Age: ≥ 65 years | 427 | 15.6% | 554 | 16.4% |
Sex: Female | 706 | 25.9% | 783 | 23.1% |
Sex: Male | 2023 | 74.1% | 2602 | 76.9% |
Race/ethnicity: White | 1945 | 71.3% | 1996 | 59.0% |
Race/ethnicity: Black | 529 | 19.4% | 965 | 28.5% |
Race/ethnicity: Hispanic | 187 | 6.9% | 325 | 9.6% |
Race/ethnicity: Asian | 47 | 1.7% | 74 | 2.2% |
Race/ethnicity: Other/unknown | 21 | 0.8% | 25 | 0.7% |
Geography: Metropolitan | 2240 | 82.1% | 2879 | 85.1% |
Geography: Non-metro | 489 | 17.9% | 506 | 14.9% |
Distance: < 50 miles | 1561 | 57.2% | 2081 | 61.5% |
Distance: 50-<100 miles | 488 | 17.9% | 537 | 15.9% |
Distance: 100-<150 miles | 278 | 10.2% | 335 | 9.9% |
Distance: 150-<250 miles | 193 | 7.1% | 210 | 6.2% |
Distance: ≥ 250 miles | 188 | 6.9% | 208 | 6.1% |
Distance: Unknown | 21 | 0.8% | 14 | 0.4% |
All candidates | 2729 | 100.0% | 3385 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Diagnosis: Coronary artery disease | 1099 | 40.3% | 978 | 28.9% |
Diagnosis: Cardiomyopathy | 1264 | 46.3% | 2015 | 59.5% |
Diagnosis: Congenital disease | 154 | 5.6% | 187 | 5.5% |
Diagnosis: Valvular disease | 57 | 2.1% | 37 | 1.1% |
Diagnosis: Other/unknown | 155 | 5.7% | 168 | 5.0% |
Blood type: A | 882 | 32.3% | 966 | 28.5% |
Blood type: B | 259 | 9.5% | 369 | 10.9% |
Blood type: AB | 43 | 1.6% | 61 | 1.8% |
Blood type: O | 1545 | 56.6% | 1989 | 58.8% |
Medical urgency: Former Status 1A | 155 | 5.7% | 0 | 0.0% |
Medical urgency: Former Status 1B | 734 | 26.9% | 0 | 0.0% |
Medical urgency: Former Status 2 | 981 | 35.9% | 1 | 0.0% |
Medical urgency: New Status 1 | 0 | 0.0% | 4 | 0.1% |
Medical urgency: New Status 2 | 0 | 0.0% | 48 | 1.4% |
Medical urgency: New Status 3 | 0 | 0.0% | 217 | 6.4% |
Medical urgency: New Status 4 | 0 | 0.0% | 1710 | 50.5% |
Medical urgency: New Status 5 | 0 | 0.0% | 108 | 3.2% |
Medical urgency: New Status 6 | 0 | 0.0% | 502 | 14.8% |
Medical urgency: Inactive | 859 | 31.5% | 795 | 23.5% |
VAD at listing | 368 | 13.5% | 1257 | 37.1% |
All candidates | 2729 | 100.0% | 3385 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Transplant history: First | 2616 | 95.9% | 3289 | 97.2% |
Transplant history: Retransplant | 113 | 4.1% | 96 | 2.8% |
Wait time: < 1 year | 1467 | 53.8% | 1616 | 47.7% |
Wait time: 1-< 2 years | 508 | 18.6% | 863 | 25.5% |
Wait time: 2-< 3 years | 223 | 8.2% | 376 | 11.1% |
Wait time: 3-< 4 years | 133 | 4.9% | 212 | 6.3% |
Wait time: 4-< 5 years | 61 | 2.2% | 119 | 3.5% |
Wait time: ≥ 5 years | 337 | 12.3% | 199 | 5.9% |
Tx type: Heart only | 2545 | 93.3% | 3022 | 89.3% |
Tx type: Heart-kidney | 94 | 3.4% | 253 | 7.5% |
Tx type: Heart-lung | 72 | 2.6% | 74 | 2.2% |
Tx type: Other | 18 | 0.7% | 36 | 1.1% |
All candidates | 2729 | 100.0% | 3385 | 100.0% |
Waiting list state | 2017 | 2018 | 2019 |
---|---|---|---|
Patients at start of year | 3703 | 3591 | 3467 |
Patients added during year | 3947 | 4072 | 4087 |
Patients removed during year | 4050 | 4187 | 4167 |
Patients at end of year | 3600 | 3476 | 3387 |
Removal reason | 2017 | 2018 | 2019 |
---|---|---|---|
Deceased donor transplant | 2820 | 2948 | 3066 |
Patient died | 302 | 273 | 199 |
Patient refused transplant | 27 | 27 | 25 |
Improved, transplant not needed | 185 | 183 | 163 |
Too sick for transplant | 294 | 280 | 261 |
Other | 420 | 476 | 453 |
Status at listing | Percent |
---|---|
1 | 80.0% |
2 | 88.6% |
3 | 76.0% |
4 | 42.2% |
5 | 35.7% |
6 | 39.2% |
Support | 2017, N | 2017, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Any life support | 2431 | 85.6% | 2519 | 81.6% |
Left ventricular assist device | 1358 | 47.8% | 1034 | 33.5% |
Intravenous inotropes | 1019 | 35.9% | 1168 | 37.8% |
Intra-aortic balloon pump | 235 | 8.3% | 917 | 29.7% |
Right ventricular assist device | 48 | 1.7% | 69 | 2.2% |
Extra corporeal membrane oxygenation | 34 | 1.2% | 184 | 6.0% |
Total artificial heart | 23 | 0.8% | 26 | 0.8% |
Ventilator | 22 | 0.8% | 76 | 2.5% |
Inhaled NO | 5 | 0.2% | 7 | 0.2% |
Prostaglandins | 1 | 0.0% | 7 | 0.2% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Age: 18-34 years | 216 | 11.5% | 377 | 12.2% |
Age: 35-49 years | 407 | 21.7% | 654 | 21.2% |
Age: 50-64 years | 969 | 51.6% | 1461 | 47.3% |
Age: ≥ 65 years | 287 | 15.3% | 596 | 19.3% |
Sex: Female | 459 | 24.4% | 877 | 28.4% |
Sex: Male | 1420 | 75.6% | 2211 | 71.6% |
Race/ethnicity: White | 1307 | 69.6% | 1924 | 62.3% |
Race/ethnicity: Black | 362 | 19.3% | 713 | 23.1% |
Race/ethnicity: Hispanic | 141 | 7.5% | 305 | 9.9% |
Race/ethnicity: Asian | 58 | 3.1% | 123 | 4.0% |
Race/ethnicity: Other/unknown | 11 | 0.6% | 23 | 0.7% |
Insurance: Private | 1031 | 54.9% | 1500 | 48.6% |
Insurance: Medicare | 573 | 30.5% | 1007 | 32.6% |
Insurance: Medicaid | 210 | 11.2% | 419 | 13.6% |
Insurance: Other government | 49 | 2.6% | 124 | 4.0% |
Insurance: Unknown | 16 | 0.9% | 38 | 1.2% |
Geography: Metropolitan | 1554 | 82.7% | 2635 | 85.3% |
Geography: Non-metro | 325 | 17.3% | 453 | 14.7% |
Distance: < 50 miles | 1122 | 59.7% | 1880 | 60.9% |
Distance: 50-<100 miles | 319 | 17.0% | 483 | 15.6% |
Distance: 100-<150 miles | 197 | 10.5% | 319 | 10.3% |
Distance: 150-<250 miles | 124 | 6.6% | 224 | 7.3% |
Distance: ≥ 250 miles | 102 | 5.4% | 152 | 4.9% |
Distance: Unknown | 15 | 0.8% | 30 | 1.0% |
All recipients | 1879 | 100.0% | 3088 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Diagnosis: Coronary artery disease | 733 | 39.0% | 859 | 27.8% |
Diagnosis: Cardiomyopathy | 1002 | 53.3% | 1930 | 62.5% |
Diagnosis: Congenital disease | 60 | 3.2% | 151 | 4.9% |
Diagnosis: Valvular disease | 41 | 2.2% | 38 | 1.2% |
Diagnosis: Other/unknown | 43 | 2.3% | 110 | 3.6% |
Blood type: A | 785 | 41.8% | 1247 | 40.4% |
Blood type: B | 278 | 14.8% | 481 | 15.6% |
Blood type: AB | 92 | 4.9% | 165 | 5.3% |
Blood type: O | 724 | 38.5% | 1195 | 38.7% |
On VAD | 721 | 38.4% | 1110 | 35.9% |
CPRA: < 1% | 1104 | 58.8% | 1408 | 45.6% |
CPRA: 1-< 20% | 384 | 20.4% | 338 | 10.9% |
CPRA: 20-< 80% | 267 | 14.2% | 492 | 15.9% |
CPRA: 80-< 98% | 59 | 3.1% | 86 | 2.8% |
CPRA: 98-100% | 24 | 1.3% | 48 | 1.6% |
CPRA: Unknown | 41 | 2.2% | 716 | 23.2% |
Medical urgency: Former Status 1A | 974 | 51.8% | 0 | 0.0% |
Medical urgency: Former Status 1B | 750 | 39.9% | 0 | 0.0% |
Medical urgency: Former Status 2 | 155 | 8.2% | 0 | 0.0% |
Medical urgency: New Status 1 | 0 | 0.0% | 289 | 9.4% |
Medical urgency: New Status 2 | 0 | 0.0% | 1456 | 47.2% |
Medical urgency: New Status 3 | 0 | 0.0% | 650 | 21.0% |
Medical urgency: New Status 4 | 0 | 0.0% | 546 | 17.7% |
Medical urgency: New Status 5 | 0 | 0.0% | 29 | 0.9% |
Medical urgency: New Status 6 | 0 | 0.0% | 118 | 3.8% |
All recipients | 1879 | 100.0% | 3088 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Wait time: < 31 days | 455 | 24.2% | 1420 | 46.0% |
Wait time: 31-60 days | 262 | 13.9% | 334 | 10.8% |
Wait time: 61-90 days | 193 | 10.3% | 204 | 6.6% |
Wait time: 3-< 6 months | 379 | 20.2% | 335 | 10.8% |
Wait time: 6-< 12 months | 322 | 17.1% | 338 | 10.9% |
Wait time: 1-< 2 years | 177 | 9.4% | 262 | 8.5% |
Wait time: ≥ 2 years | 91 | 4.8% | 195 | 6.3% |
Transplant history: First | 1815 | 96.6% | 2984 | 96.6% |
Transplant history: Retransplant | 64 | 3.4% | 104 | 3.4% |
Tx type: Heart only | 1782 | 94.8% | 2782 | 90.1% |
Tx type: Heart-lung | 24 | 1.3% | 42 | 1.4% |
Tx type: Heart-kidney | 59 | 3.1% | 213 | 6.9% |
Tx type: Heart-liver | 11 | 0.6% | 44 | 1.4% |
Tx type: Other | 3 | 0.2% | 7 | 0.2% |
All recipients | 1879 | 100.0% | 3088 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Age: < 1 year | 43 | 16.2% | 65 | 17.3% |
Age: 1-5 years | 82 | 30.8% | 120 | 32.0% |
Age: 6-10 years | 57 | 21.4% | 73 | 19.5% |
Age: 11-17 years | 84 | 31.6% | 117 | 31.2% |
Sex: Female | 102 | 38.3% | 167 | 44.5% |
Sex: Male | 164 | 61.7% | 208 | 55.5% |
Race/ethnicity: White | 149 | 56.0% | 208 | 55.5% |
Race/ethnicity: Black | 57 | 21.4% | 74 | 19.7% |
Race/ethnicity: Hispanic | 53 | 19.9% | 70 | 18.7% |
Race/ethnicity: Asian | 6 | 2.3% | 11 | 2.9% |
Race/ethnicity: Other/unknown | 1 | 0.4% | 12 | 3.2% |
Geography: Metropolitan | 232 | 87.2% | 306 | 81.6% |
Geography: Non-metro | 34 | 12.8% | 69 | 18.4% |
Distance: < 50 miles | 135 | 50.8% | 189 | 50.4% |
Distance: 50-<100 miles | 45 | 16.9% | 74 | 19.7% |
Distance: 100-<150 miles | 28 | 10.5% | 44 | 11.7% |
Distance: 150-<250 miles | 25 | 9.4% | 36 | 9.6% |
Distance: ≥ 250 miles | 29 | 10.9% | 27 | 7.2% |
Distance: Unknown | 4 | 1.5% | 5 | 1.3% |
All candidates | 266 | 100.0% | 375 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Diagnosis: Congenital defect | 131 | 49.2% | 234 | 62.4% |
Diagnosis: Idiopathic dilated CM | 58 | 21.8% | 53 | 14.1% |
Diagnosis: Familial dilated CM | 5 | 1.9% | 6 | 1.6% |
Diagnosis: Idiopathic restrictive CM | 14 | 5.3% | 10 | 2.7% |
Diagnosis: Myocarditis | 15 | 5.6% | 5 | 1.3% |
Diagnosis: Other/unknown | 43 | 16.2% | 67 | 17.9% |
Blood type: A | 74 | 27.8% | 118 | 31.5% |
Blood type: B | 34 | 12.8% | 46 | 12.3% |
Blood type: AB | 10 | 3.8% | 8 | 2.1% |
Blood type: O | 148 | 55.6% | 203 | 54.1% |
Medical urgency: Former Status 1A | 75 | 28.2% | 88 | 23.5% |
Medical urgency: Former Status 1B | 19 | 7.1% | 72 | 19.2% |
Medical urgency: Former Status 2 | 46 | 17.3% | 113 | 30.1% |
Medical urgency: Inactive | 126 | 47.4% | 102 | 27.2% |
VAD at listing | 9 | 3.4% | 20 | 5.3% |
All candidates | 266 | 100.0% | 375 | 100.0% |
Characteristic | 2009, N | 2009, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Transplant history: First | 249 | 93.6% | 357 | 95.2% |
Transplant history: Retransplant | 17 | 6.4% | 18 | 4.8% |
Wait time: < 1 year | 160 | 60.2% | 231 | 61.6% |
Wait time: 1-< 2 years | 30 | 11.3% | 67 | 17.9% |
Wait time: 2-< 3 years | 21 | 7.9% | 36 | 9.6% |
Wait time: 3-< 4 years | 8 | 3.0% | 19 | 5.1% |
Wait time: 4-< 5 years | 10 | 3.8% | 8 | 2.1% |
Wait time: ≥ 5 years | 37 | 13.9% | 14 | 3.7% |
Tx type: Heart only | 252 | 94.7% | 364 | 97.1% |
Tx type: Heart-kidney | 2 | 0.8% | 2 | 0.5% |
Tx type: Heart-lung | 11 | 4.1% | 6 | 1.6% |
Tx type: Other | 1 | 0.4% | 3 | 0.8% |
All candidates | 266 | 100.0% | 375 | 100.0% |
Waiting list state | 2017 | 2018 | 2019 |
---|---|---|---|
Patients at start of year | 364 | 382 | 392 |
Patients added during year | 636 | 707 | 694 |
Patients removed during year | 618 | 696 | 672 |
Patients at end of year | 382 | 393 | 414 |
Removal reason | 2017 | 2018 | 2019 |
---|---|---|---|
Deceased donor transplant | 443 | 484 | 519 |
Patient died | 68 | 80 | 55 |
Patient refused transplant | 0 | 2 | 3 |
Improved, transplant not needed | 55 | 62 | 43 |
Too sick for transplant | 28 | 31 | 28 |
Other | 24 | 37 | 24 |
Characteristic | 2007-09, N | 2007-09, Percent | 2017-19, N | 2017-19, Percent |
---|---|---|---|---|
Age: < 1 year | 304 | 28.6% | 364 | 25.7% |
Age: 1-5 years | 263 | 24.7% | 336 | 23.8% |
Age: 6-10 years | 153 | 14.4% | 195 | 13.8% |
Age: 11-17 years | 344 | 32.3% | 519 | 36.7% |
Sex: Female | 484 | 45.5% | 625 | 44.2% |
Sex: Male | 580 | 54.5% | 789 | 55.8% |
Race/ethnicity: White | 567 | 53.3% | 738 | 52.2% |
Race/ethnicity: Black | 212 | 19.9% | 280 | 19.8% |
Race/ethnicity: Hispanic | 197 | 18.5% | 284 | 20.1% |
Race/ethnicity: Asian | 65 | 6.1% | 69 | 4.9% |
Race/ethnicity: Other/unknown | 23 | 2.2% | 43 | 3.0% |
Insurance: Private | 513 | 48.2% | 548 | 38.8% |
Insurance: Medicaid | 426 | 40.0% | 733 | 51.8% |
Insurance: Other government | 86 | 8.1% | 96 | 6.8% |
Insurance: Unknown | 39 | 3.7% | 37 | 2.6% |
Geography: Metropolitan | 897 | 84.3% | 1142 | 80.8% |
Geography: Non-metro | 167 | 15.7% | 272 | 19.2% |
Distance: < 50 miles | 547 | 51.4% | 756 | 53.5% |
Distance: 50-<100 miles | 148 | 13.9% | 248 | 17.5% |
Distance: 100-<150 miles | 119 | 11.2% | 148 | 10.5% |
Distance: 150-<250 miles | 98 | 9.2% | 121 | 8.6% |
Distance: ≥ 250 miles | 130 | 12.2% | 112 | 7.9% |
Distance: Unknown | 22 | 2.1% | 29 | 2.1% |
All recipients | 1064 | 100.0% | 1414 | 100.0% |
Characteristic | 2007-09, N | 2007-09, Percent | 2017-19, N | 2017-19, Percent |
---|---|---|---|---|
Diagnosis: Congenital defect | 455 | 42.8% | 726 | 51.3% |
Diagnosis: Idiopathic dilated CM | 318 | 29.9% | 306 | 21.6% |
Diagnosis: Familial dilated CM | 36 | 3.4% | 79 | 5.6% |
Diagnosis: Idiopathic restrictive CM | 70 | 6.6% | 58 | 4.1% |
Diagnosis: Myocarditis | 50 | 4.7% | 38 | 2.7% |
Diagnosis: Other/unknown | 135 | 12.7% | 207 | 14.6% |
Blood type: A | 385 | 36.2% | 487 | 34.4% |
Blood type: B | 146 | 13.7% | 204 | 14.4% |
Blood type: AB | 42 | 3.9% | 66 | 4.7% |
Blood type: O | 491 | 46.1% | 657 | 46.5% |
Medical urgency: Former Status 1A | 875 | 82.2% | 1136 | 80.3% |
Medical urgency: Former Status 1B | 112 | 10.5% | 229 | 16.2% |
Medical urgency: Former Status 2 | 77 | 7.2% | 49 | 3.5% |
On VAD | 167 | 15.7% | 458 | 32.4% |
CPRA: < 1% | 599 | 56.3% | 552 | 39.0% |
CPRA: 1-< 20% | 180 | 16.9% | 188 | 13.3% |
CPRA: 20-< 80% | 138 | 13.0% | 259 | 18.3% |
CPRA: 80-< 98% | 42 | 3.9% | 74 | 5.2% |
CPRA: 98-100% | 28 | 2.6% | 57 | 4.0% |
CPRA: Unknown | 77 | 7.2% | 284 | 20.1% |
All recipients | 1064 | 100.0% | 1414 | 100.0% |
Characteristic | 2007-09, N | 2007-09, Percent | 2017-19, N | 2017-19, Percent |
---|---|---|---|---|
Wait time: < 31 days | 438 | 41.2% | 403 | 28.5% |
Wait time: 31-60 days | 205 | 19.3% | 235 | 16.6% |
Wait time: 61-90 days | 127 | 11.9% | 203 | 14.4% |
Wait time: 3-< 6 months | 152 | 14.3% | 291 | 20.6% |
Wait time: 6-< 12 months | 98 | 9.2% | 167 | 11.8% |
Wait time: 1-< 2 years | 25 | 2.3% | 83 | 5.9% |
Wait time: ≥ 2 years | 19 | 1.8% | 32 | 2.3% |
ABO: Compatible/identical | 1021 | 96.0% | 1266 | 89.5% |
ABO: Incompatible | 43 | 4.0% | 148 | 10.5% |
Transplant history: First | 990 | 93.0% | 1360 | 96.2% |
Transplant history: Retransplant | 74 | 7.0% | 54 | 3.8% |
Tx type: Heart only | 1043 | 98.0% | 1393 | 98.5% |
Tx type: Other | 1 | 0.1% | 0 | 0.0% |
Tx type: Heart-lung | 12 | 1.1% | 8 | 0.6% |
Tx type: Heart-kidney | 7 | 0.7% | 10 | 0.7% |
Tx type: Heart-liver | 1 | 0.1% | 3 | 0.2% |
All recipients | 1064 | 100.0% | 1414 | 100.0% |
Support | 2014, N | 2014, Percent | 2019, N | 2019, Percent |
---|---|---|---|---|
Any life support | 293 | 71.5% | 378 | 74.3% |
Intravenous inotropes | 198 | 48.3% | 240 | 47.2% |
Left ventricular assist device | 103 | 25.1% | 164 | 32.2% |
Ventilator | 59 | 14.4% | 53 | 10.4% |
Right ventricular assist device | 27 | 6.6% | 34 | 6.7% |
Prostaglandins | 15 | 3.7% | 8 | 1.6% |
Extra corporeal membrane oxygenation | 13 | 3.2% | 10 | 2.0% |
Inhaled NO | 8 | 2.0% | 4 | 0.8% |
Intra-aortic balloon pump | 2 | 0.5% | 4 | 0.8% |
Total artificial heart | 1 | 0.2% | 1 | 0.2% |
Donor | Recipient | CMV | EBV |
---|---|---|---|
D- | R- | 33.4% | 16.6% |
D- | R+ | 16.1% | 14.2% |
D- | R unk | 0.8% | 1.4% |
D+ | R- | 28.3% | 28.6% |
D+ | R+ | 19.8% | 36.9% |
D+ | R unk | 0.8% | 1.7% |
D unk | R- | 0.6% | 0.1% |
D unk | R+ | 0.3% | 0.4% |
D unk | R unk | 0.0% | 0.1% |